The expression of cyclooxygenase-2 and survivin in urinary bladder transitional cell carcinoma

Korean Journal of Pathology

Volumn 43, Issue 3, 2009, Pages 206-211

  Jang, Tae Jung ^a   Lee, Kyung Seob ^a  

^a Dongguk University College of Medicine   (South Korea)

Author keywords

Bladder cancer; Cyclooxygenase 2; Survivin

Indexed keywords

EID: 70349513065     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2009.43.3.206     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005; 26: 263-70.
3. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941-53.
4. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
5. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
6. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-20.
7. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004; 171: 631-5.
8. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-3.
9. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007; 109: 1106-13.
10. Hershman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-40.
11. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
12. Tsujii M, Kawano S, DuBois RN. Cyclooxyenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94: 3336-40.
13. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-50.
14. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 2003; 169: 938-42.
15. Komhoff M, Guan Y, Sharppell HW, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000; 157: 29-35.
16. Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cycooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol 2005; 37: 47-53.
17. Okajima E, Uemura H, Ohnishi S. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection. Aktuelle Urol 2003; 34: 256-8.
18. Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urol 2002; 60: 816-21.
19. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364-9.
20. Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004; 18: 206-8.
21. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006; 94: 253-8.
22. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol 2007; 104: 320-5.
23. Epstein JI, Amin MB, Reuter VR, Mosofi FK. The World Health Organization/ International Society of Urology Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22: 1435-48.
24. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-36.
25. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13: 4407-14.
26. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008; 26: 59-65.
27. Altieri DC. Survivin and apoptosis control. Adv Cancer Res 2003; 88: 31-52.
28. Pallares J, Martinez-Guitarte JL, Dolcet X, et al. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 2005; 24: 247-53.
29. Munir I, Fukunaga K, Kanasaki H, Miyazaki K, Ohba T, Okamura H. Expression of cyclooxygenase 2 by prostaglandin E2 in human endometrial adenocarcinoma cell line HEC-1B. Biol Reprod 2000; 63: 933-41.
30. Mori F, Piro FR, Della Rocca C, et al. Survivin and cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes. Histol Histopathol 2007; 22: 61-77.